What Happened in Irkutsk?

In brief: A 28-year-old technician at Russia’s Irkutsk Anti-Plague Research Institute died on October 2, 2026, after a reported laboratory exposure to Yersinia pestis. Russian authorities call it “pneumonia of unknown etiology” and deny any plague case, while the WHO, CDC, and EU press for lab confirmation. As of October 8, 2026, no secondary case has been confirmed.

On October 2, 2026, 28-year-old laboratory technician Darya Shipilova died at a hospital in Shelekhov, a town near Irkutsk in eastern Siberia. Shipilova worked at the Irkutsk Anti-Plague Research Institute of Siberia and the Far East, one of Russia’s oldest infectious disease research facilities, founded in 1934.

According to multiple Russian media reports, Shipilova accidentally broke a test tube containing live Yersinia pestis bacteria on September 25 while collecting samples. She was hospitalized days later with severe pneumonia symptoms and placed on a ventilator, but died within 48 hours.

Russia’s public health watchdog, Rospotrebnadzor, has not confirmed plague as the cause of death. Instead, it classified her illness as “pneumonia of unknown etiology” and stated that testing found no microorganisms linked to her professional activities. Nearly 200 people who had contact with Shipilova were placed under medical observation, and multiple hospitals in the Irkutsk region were put under quarantine.

As of October 8, 2026, Russia has told the World Health Organization under the International Health Regulations that “no case of plague has been recorded in Irkutsk, either in her or in anyone else,” and that monitoring of all contacts has concluded. However, the WHO has pressed for more transparency, and the U.S. State Department, CDC, and European health authorities have all stated they are closely monitoring the situation. Reports of a possible second suspected case emerged on October 7, which the Kremlin dismissed as “false.”

What Is Plague? Understanding Yersinia pestis

In brief: Plague is an acute bacterial infection caused by Yersinia pestis, a flea-borne pathogen of wild rodents. It is the same organism responsible for the Black Death and remains endemic in natural foci across Africa, Asia, and the Americas today.

Plague is an acute infectious disease caused by Yersinia pestis, a Gram-negative coccobacillus belonging to the family Enterobacteriaceae. The bacterium was first identified in 1894 by Alexandre Yersin during a plague outbreak in Hong Kong (Stenseth et al., 2008, PLoS Med).

Y. pestis evolved relatively recently, within the last several thousand years, from Yersinia pseudotuberculosis, a far less dangerous gastrointestinal pathogen. This evolutionary leap was driven largely by the acquisition of specific virulence plasmids, including the pPCP1 plasmid (encoding the plasminogen activator protease), the pMT1 plasmid (encoding the F1 capsular antigen and murine toxin), and the pCD1 plasmid (encoding the Type III secretion system and Yops effector proteins) (Rosario-Acevedo et al., 2021, Biomedicines).

Plague has shaped human history unlike any other pathogen. Three major pandemics (the Justinian Plague of 541–750 CE, the Black Death of 1346–1353, and the Third Pandemic of 1855–1960s) collectively killed an estimated 200 million people (Wang et al., 2019, NPJ Vaccines).

The Three Forms of Plague

In brief: Plague has three clinical forms. Bubonic plague (swollen lymph nodes, from flea bites) is the most common; septicemic plague attacks the bloodstream; and pneumonic plague infects the lungs and is the only form that spreads person-to-person through the air. Pneumonic plague is the form involved in the Irkutsk case.

Yersinia pestis causes three distinct clinical forms of plague, depending on the route of infection (Nelson et al., 2021, MMWR Recomm Rep):

Bubonic Plague

The most common form, accounting for approximately 80–95% of naturally occurring cases. Bubonic plague results from the bite of an infected flea carrying Y. pestis from a rodent reservoir. The bacteria travel through the lymphatic system to regional lymph nodes, causing painful, swollen lymph nodes called “buboes,” most often in the groin, armpit, or neck. Without treatment, the case fatality rate for bubonic plague is approximately 50–60%, but with appropriate antibiotic therapy, mortality drops to 8–10% (Grácio & Grácio, 2017, Biomed Res Int).

Septicemic Plague

When Y. pestis enters or spreads directly into the bloodstream without producing a visible bubo, the result is primary septicemic plague. This form can also arise secondarily from untreated bubonic plague. Septicemic plague progresses rapidly to septic shock, disseminated intravascular coagulation (DIC), and multi-organ failure. Mortality is extremely high without prompt treatment.

Pneumonic Plague

This is the form at the center of the Irkutsk case. Pneumonic plague can develop in two ways: secondary pneumonic plague, when bacteria from bubonic or septicemic plague spread to the lungs, and primary pneumonic plague, when a person directly inhales aerosolized Y. pestis, either from the respiratory droplets of an infected individual or, as may have occurred in the Irkutsk incident, from laboratory exposure.

Pneumonic plague is the most severe form of the disease and the only form capable of person-to-person airborne transmission. Without treatment, it is nearly 100% fatal. Even with appropriate antibiotic therapy, the overall death rate remains significant. A 2020 systematic review published in Emerging Infectious Diseases found that treated pneumonic plague carried a pooled mortality rate of approximately 29% across studies from 1946 to 2017 (Salam et al., 2020, Emerg Infect Dis).

How Does Pneumonic Plague Spread?

In brief: Pneumonic plague spreads through respiratory droplets during close face-to-face contact (within about 2 meters), when an infected person coughs. Its reproductive number (R₀ ≈ 1.18) is far lower than COVID-19, and it does not spread before symptoms appear, so outbreaks are typically self-limiting with basic public health measures.

Pneumonic plague is transmitted from person to person through respiratory droplets (similar mechanically to influenza or COVID-19) when an infected person coughs or sneezes. However, there are important differences that limit its pandemic potential.

Unlike SARS-CoV-2, plague requires close face-to-face contact (typically within 2 meters) for droplet transmission. The estimated basic reproductive number (R₀) for pneumonic plague is only about 1.18 in the United States, meaning each infected person transmits the disease to roughly one other person on average, far below the explosive spread seen with COVID-19 or measles (Nelson et al., 2021, MMWR). Asymptomatic transmission has never been documented.

The incubation period for primary pneumonic plague is short, typically 1 to 3 days and occasionally up to 6 days. Symptom onset is sudden: high fever, chills, headache, rapidly worsening cough, and chest pain. Hemoptysis (coughing blood) may follow. Without antibiotic treatment initiated within the first 18–24 hours of symptom onset, pneumonic plague progresses rapidly to respiratory failure, sepsis, and death (Nelson et al., 2021, MMWR Recomm Rep).

Treatment: Antibiotics Work, If Started Early Enough

In brief: Plague is curable with common antibiotics. First-line treatment is streptomycin or gentamicin, with doxycycline, ciprofloxacin, or chloramphenicol as alternatives. Early treatment is critical. Patients receiving high-efficacy antibiotics had just 9% mortality, versus 51% with inadequate therapy. Close contacts receive a 7-day course of doxycycline or ciprofloxacin as prophylaxis.

Plague is a treatable bacterial infection, and unlike many viral pandemics, effective antibiotics exist. The critical factor is speed of diagnosis and treatment initiation.

According to the most recent CDC guidelines, streptomycin (or gentamicin as a more widely available alternative) remains the first-line treatment for pneumonic and septicemic plague. Tetracyclines (particularly doxycycline), fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin), and chloramphenicol are acceptable alternatives (Nelson et al., 2021, MMWR Recomm Rep).

Analysis of U.S. plague treatment patterns from 1942 to 2018 showed that mortality among patients receiving high-efficacy antibiotics was only 9%, compared to 51% among those receiving only limited-efficacy drugs. Overall plague mortality in the U.S. dropped from 66% in the pre-antibiotic era to 16% after antimicrobials became available (Kugeler et al., 2020, Clin Infect Dis).

Post-exposure prophylaxis is recommended for all close contacts of pneumonic plague patients. The current recommendation is a 7-day course of doxycycline or ciprofloxacin, initiated as soon as possible after exposure.

The emergence of antibiotic-resistant Y. pestis strains is a concern. A naturally multidrug-resistant strain was isolated from a patient in Madagascar in 1995, carrying a transferable plasmid conferring resistance to streptomycin, chloramphenicol, tetracycline, and sulfonamides (Ansari et al., 2020, J Biosaf Biosecur). These strains are still rare, but they are a reminder of why surveillance has to be kept up.

A 2025 One Health review laid out several newer treatment and detection strategies, including bacteriophage (phage) therapy as a potential alternative to antibiotics, rapid antigen-based field diagnostics, and integrated human-animal surveillance systems designed to catch outbreaks earlier (Ciammaruconi et al., 2025, Biomedicines). New culture-independent genotyping platforms can now identify Y. pestis lineages directly from field samples within about two hours, enabling faster outbreak response in resource-limited settings (Liu et al., 2026, Virulence).

Global Plague Epidemiology: Rare but Persistent

In brief: Plague causes roughly 1,000–2,000 reported human cases worldwide each year, with a global case fatality rate around 7–8%. Madagascar accounts for about 75% of all cases. The U.S. records about 5 cases annually in its western states. The disease is rare but has never been eradicated.

Plague has not disappeared. It persists in natural foci (geographic areas where Y. pestis circulates among wild rodent populations and their fleas) on every inhabited continent except Australia.

Between 2000 and 2010, 21,725 plague cases and 1,612 deaths were reported globally to the WHO, yielding an overall case fatality rate of approximately 7.4%. The majority of cases occur in Africa, with Madagascar accounting for roughly 75% of all global plague cases reported to the WHO, with an annual incidence of 200–700 suspected cases (Randremanana et al., 2019, Lancet Infect Dis).

The most significant recent outbreak was the 2017 Madagascar epidemic, which was unusual because it was predominantly pneumonic rather than bubonic. Out of 2,414 clinically suspected cases, 1,878 (78%) were classified as pneumonic plague, with 386 probable and 32 confirmed pneumonic cases. The case fatality ratio among confirmed pneumonic plague cases was 25% (Randremanana et al., 2019, Lancet Infect Dis).

In the United States, plague is endemic in the western states. Between 2000 and 2019, a total of 107 cases and 12 deaths were reported, an average of about 5 cases per year, primarily in New Mexico, Arizona, Colorado, and California. In early 2024, an Oregon man contracted plague from his pet cat. The case occurred in January, the earliest calendar-date plague case in the state’s history, which researchers suggested may indicate a shift in the seasonality of plague transmission (DeBess et al., 2025, MMWR Morb Mortal Wkly Rep).

In China, plague is classified as a Class A infectious disease, the highest tier. A national surveillance analysis of 2010–2024 data found the current situation to be “sporadic human cases with active animal epidemics in some foci,” concentrated in the Qinghai-Tibet Plateau and Inner Mongolia natural foci, reinforcing that the threat persists even where human cases are infrequent (Bing et al., 2026, China CDC Weekly).

Russia’s Natural Plague Foci

In brief: Russia has 11 natural plague foci, mainly in the Caucasus, Caspian, Altai, Tuva, and Transbaikal regions, where Y. pestis circulates among wild rodents. Russia’s last confirmed human plague case was in 2016. The country runs a Soviet-era network of anti-plague institutes, including the Irkutsk facility, to monitor these zones.

Russia maintains 11 identified natural plague foci, concentrated in the Caucasus, Caspian region, Altai Mountains, Tuva, and Transbaikal regions. Between 2017 and 2025, plague-infected animals were detected in three of these foci: the Central Caucasus Highland, the Gorno-Altai Highland, and the Tuva Mountain focus.

Russia’s last confirmed human plague case before the current incident occurred in 2016, when a 10-year-old child in the Altai Republic fell ill. The country maintains an extensive network of anti-plague research institutes, a Soviet-era infrastructure originally built to monitor and prevent plague outbreaks in the vast territories where natural foci exist.

The Irkutsk Anti-Plague Research Institute, where Shipilova worked, was founded in 1934 and serves as a scientific and operational center for plague control across Siberia and the Russian Far East. It works with dangerous pathogens including Y. pestis as part of routine surveillance and research. The WHO noted that plague occurs naturally among wild animals in the Irkutsk region, meaning the institute’s work with live Y. pestis cultures is part of its core mission.

No Approved Plague Vaccine Exists

In brief: There is no plague vaccine licensed in the U.S. or Western Europe. A live attenuated vaccine (EV76) is used in the former Soviet Union and parts of Asia, but Western regulators have not approved it. Modern F1/V subunit candidates show promise in animals but lack proven human efficacy. The WHO added Y. pestis to its priority pathogen list in 2024.

Despite plague’s devastating history and its classification as a CDC Tier 1 select agent and potential bioterrorism weapon, there is currently no licensed plague vaccine available in western nations (Geraci et al., 2021, Appl Microbiol).

A killed whole-cell vaccine was used historically (particularly during the Vietnam War for U.S. military personnel), but it provided poor protection against pneumonic plague, required multiple doses, caused significant side effects, and is no longer manufactured in the U.S. A live attenuated vaccine (EV76 strain) has been used in the former Soviet Union and parts of Asia for over 70 years, but it is not approved by western regulatory agencies (Wang et al., 2019, NPJ Vaccines).

Modern vaccine development has focused primarily on recombinant subunit vaccines targeting two key Y. pestis antigens: the F1 capsular antigen and the LcrV (V) antigen. These F1/V subunit vaccines have shown promising results in animal models but have not yet completed human efficacy trials. A 2023 systematic review found that despite decades of research, the available evidence remains insufficient to quantify the real-world efficacy of any plague vaccine candidate (Folegatti et al., 2023, Curr Res Immunol).

In 2024, the WHO updated its priority pathogen list to include Yersinia pestis as a key re-emerging pathogen requiring urgent vaccine development, and published a Target Product Profile to guide future vaccine candidates through clinical development (Sherwood et al., 2024, NPJ Vaccines). The discovery of naturally antibiotic-resistant Y. pestis strains makes vaccine development all the more urgent: if antibiotic-resistant plague were to spread, a vaccine could be the only effective countermeasure.

Should You Be Concerned?

In brief: For people outside Russia’s Irkutsk region, the risk is very low. The WHO assessed the global risk as “very low” on October 7, 2026. The incident appears to be an isolated laboratory exposure, pneumonic plague does not spread easily, and the disease is treatable with antibiotics. The main concern is the lack of transparency from Russian authorities.

For the general public outside of Russia’s Irkutsk region, the risk from this incident is extremely low. Here’s why:

First, this appears to be a laboratory accident, not a natural outbreak. Laboratory-acquired infections, while tragic, are typically self-limiting because the source of exposure is identified and contained quickly.

Second, Russia’s international isolation (a consequence of its war in Ukraine and resulting sanctions) has significantly reduced travel between Russia and the rest of the world. The WHO noted on October 7 that the case posed “very low” risk beyond Russia’s borders, partly for this reason.

Third, pneumonic plague, despite its severity, is not easily transmissible. It requires close face-to-face contact, and its R₀ of approximately 1.18 means outbreaks tend to be self-limiting when basic public health measures (isolation, contact tracing, prophylactic antibiotics) are implemented.

Fourth, plague is treatable. Unlike novel viruses for which no treatment exists, plague responds to multiple classes of widely available antibiotics when treatment is initiated early.

The primary concern is transparency. Russia has not confirmed a plague diagnosis, has not published laboratory results, and has not named the actual pathogen responsible for Shipilova’s death. This pattern of information suppression, reminiscent of early COVID-19 reporting failures in other countries, undermines international public health surveillance and erodes trust. The WHO, CDC, and European health agencies continue to press for more data.

Frequently Asked Questions

Is the plague the same as the Black Death?

Yes. The Black Death, which killed an estimated 30–60% of Europe’s population between 1346 and 1353, was caused by the same bacterium, Yersinia pestis, that is involved in the current Irkutsk case. However, modern medicine has transformed plague from a civilization-ending catastrophe into a treatable bacterial infection. With prompt antibiotic therapy, the overall mortality rate for plague has dropped from above 60% to below 10% for bubonic plague and approximately 29% for pneumonic plague (Salam et al., 2020).

Can pneumonic plague become a global pandemic?

While pneumonic plague is the only form of plague capable of direct person-to-person spread, its pandemic potential is limited by several factors: its short incubation period means patients become symptomatic quickly (making identification easier), it requires close-range droplet contact for transmission, and effective antibiotics and prophylaxis are widely available. The R₀ of approximately 1.18 is well below the threshold for explosive exponential spread. The largest pneumonic plague outbreak of the 21st century, Madagascar in 2017, produced only 32 confirmed cases (Randremanana et al., 2019). Unlike COVID-19, where asymptomatic and presymptomatic transmission fueled global spread, plague does not spread before symptoms appear (Nelson et al., 2021).

Where does plague still exist naturally?

Plague persists in natural animal reservoirs on every inhabited continent except Australia. The most active endemic regions include central and eastern Africa (particularly Madagascar, the Democratic Republic of Congo, and Tanzania), Central Asia (Kazakhstan, Kyrgyzstan, Mongolia), China, the western United States, and parts of South America. Russia maintains 11 natural plague foci, primarily in the Caucasus, Caspian, Altai, and Transbaikal regions (Stenseth et al., 2008).

What are the first symptoms of pneumonic plague?

The first symptoms of pneumonic plague appear suddenly, typically 1 to 3 days after exposure, and include high fever, chills, severe headache, body aches, weakness, and a rapidly developing cough. Within hours, the cough may produce bloody or watery sputum, accompanied by chest pain and difficulty breathing. Because these early symptoms resemble severe pneumonia or influenza, pneumonic plague is easily misdiagnosed, which is why exposure history is critical. Without antibiotics started within roughly 24 hours of symptom onset, the disease progresses to respiratory failure and death (Nelson et al., 2021, MMWR Recomm Rep).

How is plague diagnosed?

Plague is diagnosed by detecting Yersinia pestis in body fluids: typically blood, sputum (for pneumonic plague), or fluid aspirated from a bubo (for bubonic plague). Confirmation methods include bacterial culture, polymerase chain reaction (PCR), and rapid diagnostic tests (RDTs) that detect the F1 antigen. A definitive culture takes at least 48 hours, which is why treatment is started presumptively based on clinical suspicion and exposure history before laboratory confirmation. Newer field-deployable genotyping tools can now identify Y. pestis strains directly from samples in about two hours (Liu et al., 2026, Virulence).

Can you get plague from your pet?

Yes. Domestic cats and, less commonly, dogs can contract plague by hunting infected rodents, and can transmit it to humans. Cats in particular can develop pneumonic plague and spread it through respiratory droplets or bites. In January 2024, an Oregon man contracted plague from his pet cat, the earliest-season case in that state’s recorded history (DeBess et al., 2025, MMWR). In endemic areas, keeping pets flea-treated, preventing them from hunting rodents, and seeking veterinary care for sick animals reduces this risk.

Is the Russia plague outbreak confirmed?

No. As of October 8, 2026, Russia has not officially confirmed a plague diagnosis. Russia’s public health agency, Rospotrebnadzor, states that the deceased laboratory technician had “pneumonia of unknown etiology,” and told the WHO on October 6 that “no case of plague has been recorded in Irkutsk, either in her or in anyone else.” However, Russian authorities have not published laboratory results or named the pathogen responsible. Local media and the governor of neighboring Buryatia initially reported pneumonic plague, and the WHO, CDC, and EU continue to request verifiable data. No secondary case has been confirmed.

How deadly is plague today?

With prompt antibiotic treatment, plague is far from the near-certain death sentence of the medieval era. Treated bubonic plague has a case fatality rate of approximately 8–10%, while treated pneumonic plague carries a pooled mortality of around 29%, largely because diagnosis is often delayed (Salam et al., 2020, Emerg Infect Dis). Untreated, however, bubonic plague kills 50–60% of patients, and both septicemic and pneumonic plague are nearly always fatal. The single most important determinant of survival is how quickly antibiotics are started (Kugeler et al., 2020, Clin Infect Dis).

What are the symptoms of bubonic plague?

Bubonic plague symptoms typically appear 2 to 6 days after a flea bite. The hallmark sign is one or more extremely painful, swollen lymph nodes (called buboes), usually in the groin, armpit, or neck depending on the bite location. Accompanying symptoms include sudden onset of fever (often above 38.5 °C / 101 °F), chills, severe headache, extreme fatigue, and muscle aches. The bubo itself is firm and tender to the touch, and can swell to the size of a chicken egg. If untreated, the bacteria can spread to the bloodstream (causing secondary septicemic plague) or lungs (causing secondary pneumonic plague), both of which are life-threatening. With prompt antibiotic treatment, the fatality rate for bubonic plague drops to approximately 8–10% (Grácio & Grácio, 2017).

Is the plague still around today?

Yes, plague has never been eradicated. Yersinia pestis persists in natural animal reservoirs, mainly wild rodents and their fleas, across Africa, Asia, the Americas, and parts of Europe. The WHO receives reports of roughly 1,000 to 2,000 human cases globally each year, with the majority in Madagascar, the Democratic Republic of Congo, and Peru. Russia maintains 11 active natural plague foci. China classified plague as a Class A infectious disease and reported sporadic human cases through 2024 (Bing et al., 2026). The disease has never disappeared. It is simply kept in check through surveillance, flea control, and rapid antibiotic treatment.

Is there a cure for the plague?

Yes. Plague is curable with antibiotics when treatment begins early. The primary antibiotics used are streptomycin and gentamicin (aminoglycosides), with doxycycline, ciprofloxacin, and chloramphenicol as effective alternatives. The key is timing: patients who receive high-efficacy antibiotics within the first 24 hours of symptoms have a mortality rate of roughly 9%, compared to 51% with inadequate therapy (Kugeler et al., 2020). Even pneumonic plague, the most lethal form, can be cured if diagnosed and treated promptly. Untreated plague, however, is nearly always fatal for the septicemic and pneumonic forms.

Does plague still exist in the United States?

Yes. Plague is endemic in the western United States. Between 2000 and 2019, 107 cases and 12 deaths were reported, an average of about 5 cases per year. The most affected states are New Mexico, Arizona, Colorado, California, and Oregon. Cases typically occur in rural areas where people come into contact with wild rodent flea populations. In January 2024, a man in Oregon contracted plague from his infected pet cat, the earliest-season plague case in the state’s history (DeBess et al., 2025). The CDC advises people in endemic areas to avoid handling wild rodents, use flea prevention on pets, and seek immediate medical attention for unexplained fever with lymph node swelling.

What is the difference between bubonic plague and pneumonic plague?

Bubonic and pneumonic plague are caused by the same bacterium (Yersinia pestis) but differ in how they infect the body and how they spread. Bubonic plague enters through the skin, usually via a flea bite, and infects the lymph nodes, causing painful swelling (buboes). It does not spread directly from person to person. Pneumonic plague infects the lungs, either through inhaling airborne bacteria from an infected person’s cough (primary pneumonic plague) or when untreated bubonic or septicemic plague spreads to the lungs (secondary pneumonic plague). Pneumonic plague is the only form that can spread person-to-person through the air, and it is far more deadly: untreated pneumonic plague is nearly 100% fatal, compared to about 50–60% for untreated bubonic plague. Both forms are treatable with the same antibiotics, but pneumonic plague requires faster treatment, ideally within 24 hours of symptom onset (Nelson et al., 2021).

Why is there no plague vaccine?

Despite decades of research, no plague vaccine has been approved by western regulatory agencies. The main challenges include the difficulty of conducting efficacy trials (plague is too rare for large randomized trials), the complexity of achieving protection against both bubonic and pneumonic forms, and the bacterium’s ability to suppress the host immune response through its Type III secretion system. Research currently focuses on subunit vaccines targeting the F1 and LcrV antigens, with several candidates in preclinical or early clinical development. The WHO’s 2024 inclusion of Y. pestis on its priority pathogen list may accelerate funding and development timelines (Sherwood et al., 2024).

References

  1. Stenseth NC, Atshabar BB, Begon M, et al. Plague: past, present, and future. PLoS Med. 2008;5(1):e3. PMID: 18198939
  2. Rosario-Acevedo R, Biryukov SS, Bozue JA, Cote CK. Plague Prevention and Therapy: Perspectives on Current and Future Strategies. Biomedicines. 2021;9(10):1421. PMID: 34680537
  3. Salam AP, Rojek A, Cai E, Raberahona M, Horby P. Deaths Associated with Pneumonic Plague, 1946-2017. Emerg Infect Dis. 2020;26(10):2432-2434. PMID: 32946734
  4. Randremanana R, Andrianaivoarimanana V, Nikolay B, et al. Epidemiological characteristics of an urban plague epidemic in Madagascar, August-November, 2017: an outbreak report. Lancet Infect Dis. 2019;19(5):537-545. PMID: 30930106
  5. Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS. Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response. MMWR Recomm Rep. 2021;70(3):1-27. PMID: 34264565
  6. Ansari I, Grier G, Byers M. Deliberate release: Plague – A review. J Biosaf Biosecur. 2020;2(1):10-22. PMID: 32835180
  7. Grácio AJDS, Grácio MAA. Plague: A Millenary Infectious Disease Reemerging in the XXI Century. Biomed Res Int. 2017;2017:5696542. PMID: 28904964
  8. Kugeler KJ, Mead PS, Campbell SB, Nelson CA. Antimicrobial Treatment Patterns and Illness Outcome Among United States Patients With Plague, 1942-2018. Clin Infect Dis. 2020;70(Suppl 1):S20-S26. PMID: 32435801
  9. Geraci J, et al. Plague vaccines: new developments in an ongoing search. Appl Microbiol Biotechnol. 2021;105(12):4931-4941. PMID: 34142207
  10. Folegatti PM, et al. The efficacy, safety, and immunogenicity of plague vaccines: A systematic literature review. Curr Res Immunol. 2023;4:100072. PMID: 37954941
  11. Wang X, Zhang X, Zhou D, Yang R. Plague vaccine: recent progress and prospects. NPJ Vaccines. 2019;4:11. PMID: 30792905
  12. Sherwood CA, et al. Progress on the research and development of plague vaccines with a call to action. NPJ Vaccines. 2024;9(1):162. PMID: 39242587
  13. Ciammaruconi A, et al. Plagued by the Past, Pressed by the Present: A One Health Perspective on Yersinia pestis. Biomedicines. 2025;13(10):2555. PMID: 41153833
  14. Liu Y, et al. A field-deployable high-resolution SNP genotyping platform for rapid surveillance of Yersinia pestis. Virulence. 2026;17(1):2700072. PMID: 42418343
  15. Bing Q, et al. Surveillance and Analysis of Plague Epidemic — China, 2010-2024. China CDC Wkly. 2026;8(16):463-468. PMID: 42170248
  16. DeBess E, et al. Notes from the Field: Early-Season Human Plague Transmitted from an Infected Cat — Oregon, January 2024. MMWR Morb Mortal Wkly Rep. 2025;74(26). PMID: 40674350

Last updated: October 8, 2026